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Attitude towards and factors affecting uptake of population based BRCA testing in the Ashkenazi 
Jewish population: a cohort study  
 
Objective 
To evaluate factors affecting unselected-population-based-BRCA-testing in Ashkenazi-Jews (AJ). 
Design 
Cohort-study set within recruitment to the GCaPPS-trial (ISRCTN73338115) 
Setting 
North-London AJ-population 
Population or Sample 
AJ women/men >18-years, recruited through self-referral. 
Methods 
AJ-women/men underwent pre-test counselling for BRCA-testing through recruitment clinics 
(clusters). Consenting individuals provided blood-sample for BRCA-testing. Socio-
demographic/family-history/knowledge/psychological well-being data along-with 
benefits/risks/cultural-influences (18-item-questionnaire measuring ‘attitude’) were collected. 
4-item likert-scales analysed initial ‘interest’ and ‘intention-to-test’ pre-counselling.   Uni-&-
multivariable logistic-regression-models evaluated factors affecting uptake/interest/intention-to 
undergo BRCA-testing. Statistical inference was based on cluster robust standard-errors and joint 
Wald-tests for significance. Item-Response-Theory and graded-response-models modelled responses 
to 18-item questionnaire.  
Main Outcome Measures: 
Interest, intention, uptake, attitude towards BRCA-testing 
Results 
935 (women=67%/men=33%; mean-age=53.8(S.D=15.02) years) individuals underwent pre-test 
genetic-counselling.   Pre-counselling 96% expressed interest but 60% indicated clear intention-to 
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undergo BRCA-testing. Subsequently 88% opted for BRCA-testing. BRCA-related knowledge 
(p=0.013) and degree-level education(p=0.01) were positively and negatively (respectively) 
associated with intention-to-test. Being married/cohabiting had four-fold higher-odds for BRCA-
testing uptake (p=0.009). Perceived benefits were associated with higher pre-counselling odds for 
interest and intention-to undergo BRCA-testing. Reduced uncertainty/reassurance were the most 
important factors contributing to decision-making. Increased importance/concern towards 
risks/limitations (confidentiality/insurance/emotional-impact/inability to prevent cancer/marriage-
ability/ethnic-focus/stigmatization) were significantly associated with lower-odds of uptake-of BRCA-
testing, and discriminated between acceptors and decliners. Male-gender/degree-level-education 
(p=0.001) had weaker, while having children had stronger (p=0.005) attitudes towards BRCA-testing.  
Conclusions 
BRCA-testing in the AJ-population has high acceptability. Pre-test counselling increases awareness of 
disadvantages/limitations of BRCA-testing, influencing final cost-benefit perception and decision-
making on undergoing testing.  
Funding 
The Eve-Appeal Charity (Grant-GTCV) 
Key Words 
BRCA, genetic-testing, population-based, Ashkenazi-Jewish, attitude, uptake, interest, intention. 
Tweetable Abstract 
BRCA testing in Ashkenazi Jews has high acceptability and uptake. Pre-test counselling facilitates 
informed decision making. 
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Attitude towards and Factors affecting uptake of Population based BRCA testing in the Ashkenazi 
Jewish population: a cohort study  
 
INTRODUCTION 
Unselected population-based Founder Mutation BRCA-testing in the Ashkenazi-Jewish (AJ) 
population has been investigated in the UK Genetic Cancer-Prediction through Population-Screening 
(GCaPPS) randomised-controlled trial (RCT) (ISRCTN73338115),1 as well as in Israeli2 and Canadian3 
single-arm cohort studies. The GCaPPS trial offered pre-test counselling outside a hospital in a high-
street/community-based setting. Both traditional face-to-face and DVD-based approaches were 
compared and found to be equivalent.4 The Israeli/Canadian studies provided only post-test 
counselling to mutation carriers or those with a strong family-history (FH) of cancer. High 
satisfaction rates have been reported in all three studies.1, 4-6 A population-based approach identifies 
>50% additional BRCA-carriers than clinical-criteria/FH-based testing, does not detrimentally affect 
psychological well-being or quality-of-life on a population basis1, 5 and has been found to be 
extremely cost-effective.7 This has led to calls by a number of experts for changing the paradigm to 
population-based BRCA-testing in the AJ-population.8, 9  
 
Only limited data exist on attitude and factors affecting uptake of population-based BRCA-testing in 
the Jewish population, and these are largely restricted to women.5, 10 Differences have also been 
reported between those who are self-referred and those recruited through clinical services.5 The 
Jewish-population is the first population for whom population-based BRCA-testing is likely to 
become a reality. Understanding attitudes and factors affecting uptake are essential to help in the 
planning of clinical services, supportive care/interventions and future genetic testing programmes. 
In this paper we describe the attitudes towards and factors affecting uptake as well as interest, and 
intention-to-access population-based BRCA-testing amongst AJ women and men.  
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METHODS 
GCaPPS participants were recruited from the North-London Jewish community. Recruitment was 
based on self-referral.1 Study flyers were made available through community charities, a high-street 
pharmacy (Boots), select GP-practices and a web-site. Inclusion and exclusion criteria have been 
described earlier.1 Individuals expressing an interest registered with the study team and were sent a 
detailed trial information booklet. Pre-test counselling was undertaken through six high-
street/community-based centres in London.1 Recruitment clinics (clusters) were randomised to 
traditional face-to-face and DVD-counselling approaches between 2009-2010, outcomes from which 
were reported earlier.4 We report on data from individuals who underwent pre-test counselling in 
recruitment clinic clusters. Genetic-counselling was undertaken by a qualified genetic-counsellor and 
a clinical-fellow experienced in cancer-genetics risk-assessment and management. It covered FH, 
cancer risk, genetic inheritance, risk management, psychosocial implications, and 
advantages/disadvantages to meet counselling goals11-13 and enable informed choice and 
adaptation. Individuals opting for genetic-testing provided a blood sample for the three AJ BRCA 
founder-mutations: 185delAG(c.68_69delAG), 5382insC(c.5266dupC) and 6174delT(c.5946delT).  
A baseline questionnaire assessed socio-demographic characteristics and FH. Knowledge was 
assessed by a specially developed 10-item (True=1/False=0) questionnaire described earlier.4 
Anxiety/depression were assessed by the Hospital anxiety-&-depression scale (HADS).14 Attitude 
towards BRCA-testing was assessed by an 18-item questionnaire (Appendix -S1) comprising: (a) 7-
items assessing perceived benefits (to be reassured, enhance cancer prevention, learn about my 
children’s risk, make decision about preventive surgery, make childbearing decisions, know if I need 
to get cancer screening, reduce uncertainty); (b) 7-items assessing perceived limitations/risks 
(worried about insurance, loss of confidentiality, stigmatization, don’t trust modern medicine, 
nothing can be done to prevent cancer, concerned about impact on family, unable to handle it 
emotionally); and (c) 4-items assessing cultural/religious influences (too focused on Jewish 
community, marriage-ability, singling out individuals of a particular ethnic group, altruism). A likert-
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scale assessed the level of importance participants attached to each of these items (1=not-at-all 
important, 2=somewhat important, 3=very important; or 1=definitely not, 2=somewhat and 
3=definitely).The 14-items in sections (a) and (b) were taken from Lerman15, 16 and have been used 
by others17, 18. Items in section-(c) were adapted from Phillips19 and Andrews20.  
 
Uptake of testing was calculated by the proportion of individuals who underwent BRCA- testing 
following pre-test counselling. Initial pre-counselling ‘interest’ to undergo testing was measured 
with: ‘If it were available to you now, would you, in the next 6-months, have a BRCA-test to see if 
you are at risk of developing cancer in the future?’ Response options: ‘yes-definitely’/‘yes-
probably’/‘no probably-not’/‘no definitely-not’.  This item was adapted from previous research 
(Sanderson)21-23, and chosen on the basis that the 6-month time frame made the hypothetical 
question more concrete and is the period about as far into the future that most people plan a 
specific change in behaviour.24 Pre-counselling ‘intention-to’ take the BRCA-test was assessed with 
an item adapted from Lerman15 and Schwartz18:  At the present time, which of the following 
statements describes you best? Response options: Haven’t thought about it/not considering BRCA-
testing; Considering BRCA-testing; Probably-will have BRCA-testing; Definitely-will have BRCA-
testing.  
 
Statistical analysis: 
Baseline characteristics were calculated using descriptive statistics.  
Interest, Intention and Uptake of BRCA-testing: 
Socio-demographic factors of interest and their relationship with 1) interest-in BRCA-testing, 2) 
intention-to undergo BRCA-testing and 3) uptake of BRCA-testing were explored in logistic-
regression models in both univariable and multivariable settings. Specifically, 1) and 2) used an 
ordinal regression-model as the outcome variables contained 4 clearly ordered options (listed 
above), whereas the uptake model used binary logistic-regression (“Acceptor/Decliner”). All models 
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were regressed on the factors: gender (men versus women), marital-status (married/cohabiting 
versus widowed/divorced/single), income (£10,000-to-<£20,000, £20,000-to-<£30,000, £30,000-to-
<£40,000, £40,000-to-<£50,000 and >£50,000 versus <£10,000), education (degree-level/above 
versus no formal qualification/GCSE/O-level/CSE/NVQ1/NVQ2/A-level education), family-history 
(low-risk versus high-risk), Having children (yes versus no), age, HADs score, cancer-risk perception 
scale and a BRCA-knowledge score. Statistical inference was based on cluster robust standard errors, 
with the cluster based on counselling clinics. Joint Wald tests were used to test the joint significance 
of more than one parameter. 
 Attitudes to BRCA-Testing- Item Response Theory: 
The Item-Response Theory (IRT) was used to model responses of the 935 volunteers to the 18-items 
(covering positive-reasoning/negative-reasoning/cultural issues) regarding attitudes to BRCA-testing. 
IRT is a unified methodology for measuring of both individuals in terms of an unobserved latent trait 
(‘ability’) and the items themselves from the administered instrument on the same metric. Statistical 
models are used to relate the responses to the items in terms of item ‘difficulty’ and item 
‘discrimination’. Difficulty reflects the location of the item on the continuous trait, specifically the 
point where the item is successfully responded to with 50% probability. Discrimination reflects the 
steepness of the s-shaped (logistic) curve meaning how quickly the probability of ‘success’ changes 
with ability values near the item difficulty. A steeper item implies an item better able to discriminate 
between individuals closely placed on the continuum. Advantages of IRT over more common and 
simplistic methods of scoring include: the allowance for missing data– the latent value is estimated 
simply on the items that have been answered, and so is not generally test-dependent; the ability to 
compare item and individual simultaneously; and the characterisation of statistical uncertainty 
regarding parameters and scores.  
 
In IRT the items are modelled by a collective set of logistic-regression type models. However, the 
items are ‘regressed’ on the latent trait which is unobserved. Hence, the trait is assumed to be 
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(standard) normally distributed and marginal maximum-likelihood estimation is used, with the 
assumed latent distribution integrated out. Because the items used in the (attitude to BRCA-testing) 
scale each have multiple responses in a naturally ordered manner (“Not-at-all important/Somewhat-
important/Very-important”) we have used the graded response model (GRM) for each item, 
analogous to ordered logistic-regression. For each item category boundary there is a difficulty 
estimate (between “Not-at-all important/Somewhat important” and between “Somewhat-
important/Very-important”) and a single discrimination parameter for each of the 18-items. 
Graphical methods used to display the GRM include: boundary characteristic curves (BCCs - where 
the next category becomes more likely), category characteristic curves (CCCs – the probability of 
response for each item category along the continuum), individual and overall item information 
functions (IIFs – showing the amount of statistical information reflected by the item or the scale as a 
whole, respectively), and the density plot of the scores. Attitudes to testing scores for each 
individual based on their response pattern were calculated marginally by integrating over the latent 
trait distribution and using the posterior-mean. The distribution of scores was investigated with a 
kernel density-plot. The association of socio-demographic factors with the GRM attitude to testing 
scores were also explored with multivariable linear regression. 
Funding:  The study underwent peer review and was funded by The Eve Appeal Charity (Grant award 
number- GTCV). The funding body (The Eve Appeal charity) had no role in the study design, data 
collection, analysis, interpretation or writing of the report or decision to submit for publication. The 
research team was independent of funders.  
Core Outcome Sets (COS): There are no Core Outcome Sets for population or BRCA testing at 
present. 
Patient & Public Involvement (PPI): The research team undertook an extensive community 
engagement exercise prior to commencement of the study. This included meetings with decision 
makers, Rabbis, Jewish Medical Association, numerous Jewish Charities and stakeholders across all 
sections of the Jewish community (e.g. Orthodox, Liberal, Reform, Masorti and Unaffiliated). This 
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was essential to understand the perspectives of all community stakeholders, address concerns, 
ensure stakeholder management, increase engagement and awareness as well as facilitate 
development and delivery of study. PPI stakeholders contributed to development and design of 
study materials, provided representation on the Trial Steering committee and also provided 
community based premises for conduct of the study. Supporting charities and organisations helped 
increase awareness of the study through organising workshops, meetings and newsletters. Feedback 
received highlighted the importance of having community based easily accessible centres for 
counselling (non-hospital settings) to promote anonymity and easy access. Charities- Jewish Care, 
Norwood, Agudas Israeli Housing Association provided premises for pre and post-test counselling. 
Input into patient facing document design helped highlight sensitive issues around testing and avoid 
anything the public may find insensitive or potentially offensive. The study title was also modified 
following feedback from the community. A cooling off period of 2 weeks was introduced to enable 
withdrawal in case people changed their minds. This PPI exercise was critical for the success of the 
study. BRCA testing is a sensitive issue and can lead to a range of opinions and emotions. It 
highlighted issues of concern in the community which were addressed by the study team prior to 
commencement of the study and also provided an opportunity of engagement to reassure 
stakeholders on the structure and governance around the study as well as the necessity and 
commitment to informed consent. 
RESULTS 
Overall 935 people underwent pre-test genetic-counselling in recruitment clinic clusters (256 
Clusters, mean cluster size= 3.64) in the GCaPPS study. The mean age of participants was 53.8 
(S.D=15.02) years. Table-1 describes the baseline characteristics of the cohort. Pre-counselling levels 
of ‘interest’ were much higher than levels of any clear ‘intention’ to undergo BRCA-testing (Table-1).  
While 96% expressed interest, only 60% indicated clear intention to undergo BRCA-testing pre-
counselling. Overall 88% subsequently opted for BRCA-testing. Of these 67% were women (33% 
men), 59% had degree or higher level of education and 79% were married/cohabiting.  
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The association of socio-demographic variables with uptake, intention and interest in BRCA-testing 
observed on uni-variable and multi-variable logistic-regression analyses are described in Table-2. 
Increased cancer risk perception was significantly associated with higher levels of interest-in testing 
(p=0.017). Higher education level was associated with reduced intention-to test (p=0.033). However, 
higher levels of BRCA-related knowledge were associated with increased interest (p=0.012), 
intention-to test (p=0.003) as well as increased uptake of BRCA-testing (p=0.002). Increased anxiety 
(anxiety HADS p= 0.009; total HADS p=0.016) was associated with reduced uptake of BRCA-testing. 
Multivariable modelling confirmed that knowledge (p=0.013) and education (p=0.01) remained 
significantly associated with intention-to test, while being married/cohabiting was associated with 
four-fold higher odds of uptake of BRCA-testing (p=0.009) (Table-2). We did not find a statistically 
significant association of FH, gender, income or age with uptake/intention/interest in BRCA-testing. 
 
The association of perceived benefits, risks and cultural factors with uptake of BRCA-testing as well 
as prior ‘intention-to’ test and ‘interest’ in BRCA-testing are given in Table-3. The various perceived 
benefits of BRCA-testing were significantly associated with higher pre-counselling odds of interest 
and intention to undergo BRCA-testing but not with actual uptake of testing (except to make 
childbearing decisions) (Table-3). The risks associated with insurance, confidentiality, emotional 
impact, inability to prevent cancer/lack of trust in modern medicine, were negatively associated with 
interest but not associated with intention-to undergo testing. However, increased importance 
attached to all the risks/limitations were significantly associated with lower-odds of uptake of BRCA-
testing (Table-3). Increased levels of concern associated with focus on the Jewish ethnic community, 
singling out an ethnic group and marriage-ability were associated significantly lower 
interest/intention and lower odds of uptake of BRCA-testing. Altruism did not affect intention or 
uptake of BRCA-testing (Table-S1).  
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The individual item information functions (IIFs – showing the amount of statistical information 
reflected by each item of the scale) is given in Figure-S1. It suggests that reduction in uncertainty and 
reassurance were the most important of all factors associated with BRCA-testing. The category 
characteristic curves for the GRM are given in Figure-S2 and the boundary characteristic curves 
(BCCs) are given in Figure-S3. The density plot of the scores had a normal distribution and is given in 
Figure-S4. Table-4 provides the association of socio-demographic variables with the overall GRM 
attitude to testing (benefits/risks/cultural factors) scores. Men (p=0.001) and those with higher 
education (p=0.001) had lower attitude scores while those with children had higher scores (p=0.005) 
associated with BRCA-testing.   
 
DISCUSSION 
Main Findings 
We found a high uptake of BRCA-testing (88%) reconfirming the broad acceptability/support for 
BRCA-testing in the AJ-population. The apparent benefits of cancer prevention, screening, 
reassurance, information about children’s risk and reduction in uncertainty were major motivators 
for BRCA-testing. However, it was perceived disadvantages and cultural factors (not benefits) that 
were statistically significantly associated with final ‘uptake’ (lower odds) of BRCA-testing and 
differentiated ‘acceptors’ from ‘decliners’. Marriage-ability, ethnic focus, stigmatization, 
confidentiality, insurance and emotional impact were concerns for some participants and associated 
with lower odds of undergoing BRCA-testing.  Pre-test counselling enabled informed decision-
making on uptake of testing. People with stronger attitudes towards BRCA-testing included women, 
those with less than degree level education and those with children. However, individuals with a 
PhD/Masters/Bachelors’ degree had weaker attitude and lower levels of initial ‘intention’ than those 
with lower/no qualifications 
 
Strengths and Limitations: 
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Strengths of our study include its population-based ascertainment, pre-test counselling for all, and 
presence of women and male participants. Our study population is likely to represent a good 
estimate and distribution of the characteristics of people who may come forward for population-
based BRCA-testing should it be offered in the future. A limitation is lack of qualitative data on 
factors affecting attitude/uptake on BRCA-testing. Nevertheless, a number of our findings are 
consistent with qualitative data reported by others.10  
 
Interpretation  
Our findings of BRCA-testing acceptability are consistent with reports from Israel and Canada.3, 5, 10 
Our uptake was slightly higher than the 67% reported in the Israeli study.5 This could be due to 
population differences or recruitment location. Uptake rates appear to be higher when testing 
services are delivered in the community. Uptake rates reported in ambulatory clinics in the Israeli 
study were similar to ours. An extensive community engagement exercise undertaken during study 
development highlighted the importance of providing testing within the community outside a 
hospital environment and facilitated uptake. Additionally our study included standardised pre-test 
counselling. 
 
Motivators for BRCA-testing observed by us have also been reported in the Israeli population-testing 
study,10  telephone surveys17, 25 and interviews with high-risk AJ women.19 While potential 
discrimination concerns some people, this is not widespread in the majority of the population. 
Unlike earlier reports19 we did not find altruism to be associated with uptake of BRCA-testing. Our 
findings in the low-risk AJ-population are consistent with some reports from high-risk clinics,15, 16 and 
indicate that people initially coming forward for BRCA-testing are better informed of its benefits, and 
rate these higher, while giving less consideration to limitations/risks. Our results suggest education 
and counselling in an unselected-Jewish-population leads to increased awareness of disadvantages 
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of BRCA-testing which does influence the final cost-benefit perception and choices people make.15, 16, 
18 
 
The high level of initial ‘interest’ in BRCA-testing seen in our participants is consistent with self-
referral. It has also been reflected in recruitment to the Israeli/Canadian studies and reported in 
earlier smaller studies of varying ascertainment.25-27 However, only 60% of participants indicated a 
clear ‘intention-to’ undergo testing before counselling. That 88% of attendees eventually consented 
to genetic-testing suggests that BRCA-testing may be acceptable to a large proportion of the AJ-
population and reflects the impact of pre-test education/counselling on informed decision-making. 
Most of the 40% who had not thought about/would not consider/were still considering BRCA1/2-
testing opted to proceed with testing.  
 
The items used by us for evaluating benefits/risks/cultural influences (attitude) towards BRCA-
testing have been adapted from items previously described and used by others in high-risk 
populations15, 16, 19, 20 and appear reliable and reproducible in a lower-risk population unselected for 
FH. The gender based differences in attitude is an interesting finding and explains why 30% more 
women came forward for testing compared to men.  Limited data exist on differences between men 
and women towards BRCA1/2-testing. The main predictors reported for men include need to know 
about children’s risk and influence of women/other carriers in the family.28-30 Men have been stated 
to be less likely than women to alter screening practices, require support or experience a changed 
psychological state.31 Any population-screening programme will need to better understand and 
address the concerns of men. We found attitudinal factors were independent of FH of cancer. A 
positive correlation of attitude with knowledge15 and FH15 as well as an inverse18 correlation with FH 
has been previously reported. The mean age (53.8 years) of study participants was slightly older and 
probably reflects, the age distribution of individuals proactively coming forward for testing in the 
study (self-referral based recruitment), greater awareness of these issues at older ages, the 
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significantly older age of the Jewish population compared to the non-Jewish population in the UK (44 
vs 38 years for women and 41 vs 36 years for men),32 as well as the likelihood that older individuals 
are more likely to be married (a factor significantly associated with uptake of testing). Nevertheless, 
study participants had a broad range of ages ranging from 18 years to 88 years, with 12% being <35 
years and 21% <40 years. Our analyses are adjusted for age of participants and we did not find age 
to affect interest/intention/uptake or overall attitude towards BRCA-testing. 
 
Our finding that individuals who were married/cohabiting were more likely to undergo BRCA-testing 
could partly reflect the importance of genetic-testing on marriage-ability in Jewish-communities and 
impact of our highlighting this issue at counselling prior to decision making. Baseline knowledge 
showed a significant association with final uptake as well as initial interest/intention for BRCA-
testing. Baseline knowledge of volunteers in our study is higher than earlier reports.18, 33 This may 
reflect increasing public awareness and easier access to information on genes, cancer-risk and 
genetic-testing over the last decade. Higher levels of education are linked to increased concern 
regarding genetic-discrimination and may explain our findings of an inverse association with BRCA-
testing.17 Our findings are consistent with earlier reports which found education25 to be inversely 
correlated, knowledge15 positively correlated and FH or age to lack correlation19, 33  with intention-to-
test.  However, a positive correlation with FH15, 18 and none with education19 has also been reported. 
 
The decision to undergo genetic-testing falls under the category of health decisions where there is 
no single paramount choice but the decision needs to be individualised depending on how the 
person values benefits/harms of the intervention. This can be complex, potentially difficult and 
dependent on numerous factors. Each factor has benefits and risks that people may value 
differently. It is important that individuals reflect on positive/negative consequences for informed 
decision making34, 35 based on their values/opinions. We found pre-test counselling in a low-risk 
population helped participants to weigh up the consequences of testing and enabled informed 
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decision making. Recent Canadian3, 6 and Israeli36 single arm population-based studies provided post-
test-counselling but not pre-test-counselling . Reports from the Canadian study suggest 58.5% 
women who tested positive and 19% overall would have preferred the opportunity to have had pre-
test counselling.6 Nevertheless both ‘pre-test’ and ‘post-test only’ counselling approaches explored 
in all three population studies report similar and extremely high-levels of overall satisfaction of 91-
95% with the testing process. Earlier randomised-trials found standard face-to-face pre-test 
counselling comparable with pre-test telephone, DVD-based and tele-genetic counselling.4, 37-40 The 
changing landscape, increasing awareness and expanding applicability enabling large scale high 
volume genetic-testing has resulted in exploration of novel approaches with a move away from 
traditional face-to-face counselling. A web-based decision-aid and telephone helpline approach for 
pre-test decision making is being piloted in a pilot population-based panel-testing study (PROMISE 
feasibility-study).41  However, there are currently no randomised data comparing pre-test 
counselling with ‘no pre-test’ or ‘only post-test’ counselling. This topic remains an important area for 
future research.  
 
Conclusion 
BRCA-testing is acceptable to a large proportion of AJ. Our findings show that a number of factors 
affecting BRCA-testing in a low-risk AJ population are similar to those previously reported from high-
risk clinics. These data would be of interest to planners of genetic services and any population-based 
programme should this be instituted in the future. Pre-test counselling in the population-testing 
setting too facilitates informed-decision-making on BRCA-testing. Further research is needed to 
robustly compare pre-test counselling (current standard-of-care) with newer approaches such as 
pre-test decision-aids and/or helpline alone. 
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Table-1: Baseline description of cohort 
 N=935   Mean S.D 
Age  Age in years  53.8 15.02  
Number of Clusters    256   
Mean Cluster size   3.64    
HADS 
  
  
HADS Anxiety 6.25 3.6 
HADS Depression 2.92 2.57 
HADS Total 9.18 5.36 
Baseline Knowledge Knowledge Score (S.D) 8.3 2.09 
    n % 
Gender 
  
Female 625 0.6684 
Male 310 0.3316 
Children 
  
yes 744 0.8185 
no 165 0.1815 
Marital Status 
  
Single/Divorced/Separated/ 
Widowed 
196 0.2137 
Married/Cohabiting 721 0.7863 
Education 
  
Below degree Level (No-Formal- 
Qualification/ GCSE, O-level, CSE/ 
NVQ1,NVQ2/ A-level,NVQ-3/ 
NVQ-4) 
361 0.4065 
Degree level or above 
(Bachelors/ Masters/ Phd) 
527 0.5935 
Income (£)  
(K=thousand) 
  
  
  
  
  
<10K 42 0.0518 
10K-19.9K 64 0.0789 
20K-29.9K 82 0.1011 
30K-39.9K 99 0.1221 
40K-49.9K 92 0.1134 
≥50K 432 0.5327 
Interest: Would 
you, in the next 6 
months, have a 
BRCA1/2 genetic 
test  
No Definitely Not 4 0.0046 
No Probably not 24 0.0278 
Yes Probably 293 0.3399 
Yes Definitely 541 0.6276 
Intention: At the 
present time, what 
describes you best  
Haven’t thought about it/ Not 
considering BRCA1/2 testing 203 0.2358 
Considering BRCA1/2 testing 141 0.1638 
Probably will have BRCA1/2 
testing 178 0.2067 
Definitely will have BRCA1/2 
testing 339 0.3937 
Uptake of genetic 
testing 
Acceptors (Yes) 826 0.8834 
Decliners (No) 109 0.1166 
 
FH- family history, HADS- hospital anxiety and depression scale, S.D – Standard Deviation 
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Table-2: Factors affecting Uptake, Intention and Interest in undergoing BRCA-testing 
MULTIVARIABLE 
MODELS FOR 
UPTAKE, INTENTION 
& INTEREST 
 Uptake Model  Intention Model Interest Model 
 OR SE P>|z| 95% CI OR SE P>|z| 95% CI OR SE P>|z| 95% CI 
Gender  0.73 0.283 0.473 0.31, 1.72 1.22 0.217 0.258 0.87, 1.71 1.05 0.229 0.819 0.69, 1.61 
Family History 0.66 0.473 0.565 0.16, 2.69 0.69 0.173 0.138 0.42, 1.13 0.8 0.229 0.432 0.45, 1.4 
Income (£)                         
10K-20K (£) 0.59 0.702 0.656 0.06, 6.12 0.73 0.399 0.56 0.25, 2.13 0.94 0.584 0.917 0.28, 3.18 
20K-30K (£) 0.32 0.381 0.339 0.03, 3.29 0.82 0.462 0.722 0.27, 2.48 1.31 0.788 0.647 0.41, 4.25 
30K-40K (£) 1.64 2.217 0.716 0.12, 23.27 0.69 0.375 0.494 0.24, 2.01 0.91 0.538 0.869 0.28, 2.9 
40K-50K (£) 1       0.65 0.319 0.381 0.25, 1.7 1.1 0.615 0.858 0.37, 3.29 
>50K (£) 0.46 0.48 0.457 0.06, 3.58 0.6 0.277 0.268 0.24, 1.48 1.05 0.553 0.92 0.38, 2.95 
Children  0.38 0.273 0.178 0.09, 1.56 0.76 0.218 0.343 0.43, 1.34 0.78 0.236 0.414 0.43, 1.41 
Education 1.79 0.925 0.261 0.65, 4.93 0.64 0.111 0.01 0.46, 0.09 0.8 0.172 0.306 0.53, 1.22 
Marital Status 4.03 2.159 0.009 1.41, 11.52 1.17 0.311 0.563 0.69, 1.97 1.47 0.417 0.17 0.85, 2.57 
Age 1.01 0.017 0.403 0.98, 1.05 1.01 0.007 0.137 0.99, 1.02 1.01 0.008 0.145 0.99, 1.03 
HADS Total 0.99 0.033 0.814 0.93, 1.06 0.97 0.016 0.07 0.94, 1.03 0.96 0.019 0.052 0.92, 1.0 
Knowledge 1.03 0.138 0.826 0.79, 1.34 1.17 0.049 0.013 1.02, 1.22 1.1 0.059 0.075 0.99, 1.22 
Cancer Risk Perception 0.999 0.002 0.658 0.99, 1.002 1.002 0.003 0.402 0.997, 1.008 1.01 0.004 0.079 0.999, 1.02 
UNIVARIATE MODELS 
FOR UPTAKE, 
INTENTION & 
INTEREST 
 Uptake  Intention  Interest 
 OR SE P>|z| 95% CI OR SE P>|z| 95% CI OR SE P>|z| 95% CI 
Gender  0.871 0.164 0.463  0.601, 1.261 0.902 0.120 0.441  0.694, 1.172 0.890 0.134 0.446  0.663, 1.198 
Family History 0.62 0.296 0.316 0.243, 1.58 0.734 0.149 0.127  0.494, 1.091 0.750 0.170 0.202 0.478, 1.168 
Income (£)     0.621       0.569       0.893 
 
10K-20K (£) 2.022 1.303 0.274  0.573, 7.146 1.220 0.447 0.588  0.595, 2.502 0.860 0.380 0.734 0.363, 2.045 
20K-30K (£) 0.986 0.558 0.980  0.325, 2.991 1.194 0.422 0.616  0.598, 2.386 0.860 0.358 0.711 0.377, 1.946 
30K-40K (£) 2.253 1.435 0.202  0.647, 7.851 1.410 0.509 0.342  0.694, 2.862 1.100 0.475 0.734 0.512, 2.585 
40K-50K (£) 1.580 0.938 0.440  0.494, 5.060 1.089 0.381 0.808  0.548, 2.161 0.930 0.369 0.861 0.430, 2.024 
>50K (£) 1.371 0.664 0.514  0.531, 3.544 0.966 0.290 0.909  0.536, 1.741 1.060 0.379 0.854 0.532, 2.142 
Children  0.972 0.262 0.917  0.572, 1.651 0.885 0.158 0.495  0.624, 1.256 0.910 0.175 0.613 0.621, 1.325 
Education 1.260 0.275 0.288  0.822, 1.936 0.774 0.093 0.033  0.612, 0.979 0.910 0.131 0.508 0.686, 1.206 
Marital Status 1.525 0.383 0.093  0.932, 2.496 1.136 0.173 0.403  0.842, 1.532 1.340 0.229 0.083 0.96, 1.87 
Age 0.987 0.008 0.112  0.970, 1.003 0.997 0.004 0.441  0.988, 1.005 0.990 0.005 0.244 0.984, 1.004 
HADS Total 0.960 0.017 0.016  0.925, 0.992 0.988 0.012 0.342  0.964, 1.013 0.980 0.013 0.115 0.953, 1.005 
HADS Anxiety 0.930 0.026 0.009  0.879, 0.982 0.991 0.018 0.597  0.957, 1.026 0.970 0.019 0.107 0.932, 1.007 
HADS Depression 0.950 0.037 0.233  0.883, 1.031 0.964 0.026 0.178  0.915, 1.017 0.970 0.029 0.289 0.92, 1.03 
Knowledge 1.180 0.063 0.002 1.062, 1.311 1.103 0.036 0.003 1.035, 1.175 1.090 0.039 0.012 1.02, 1.17 
Cancer Risk Perception 0.998 0.002 0.500 0.995, 1.002 1.003 0.003 0.352 0.997, 1.008 1.008 0.003 0.017 1.001, 1.015 
OR- odds ratio; SE- standard error, K- thousand, HADS- hospital anxiety and depression scale, CI- confidence interval. 
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Table-3: Attitudes towards BRCA-testing  
FACTORS    Uptake     Intention     Interest     
BENEFITS   OR SE P >Chisq 95% CI OR SE P >Chisq 95% CI OR SE P >Chisq 95% CI 
To be reassured 
  
Somewhat imp  0.188 -2.36 0.0618 0.047, 0.753 1.18 0.248 0.0001 0.779, 1.779 1.26 0.303 <0.0005 0.790, 2.021 
Very imp 0.188 -2.25   0.044, 0.805 2 0.425   1.319, 3.034 2.49 0.612   1.539, 4.031 
To enhance cancer 
prevention 
Somewhat imp 1.4 0.537 0.3772 0.662, 2.970 1.39 0.659 0.0062 0.555, 3.524 1.25 0.571 <0.0005 0.512, 3.061 
Very imp *      2.19 0.999   0.900, 5.360 3.03 1.36   1.257, 7.303 
To learn about my children’s 
risk 
Somewhat imp  1.03 0.327 0.935 0.550, 1.916 1.19 0.55 0.0019 0.480, 2.947 1.08 0.547 0.0009 0.401, 2.917 
Very imp *      1.96 0.859   0.835, 4.630 2.08 1.01   0.798, 5.412 
To make a decision about 
preventive surgery  
Somewhat imp 1.02 0.373 0.597 0.499, 2.091 1.04 0.21 0.016 0.706, 1.553 0.93 0.212 0.0003 0.595, 1.457 
Very imp 1.43 0.54   0.682, 2.999 1.61 0.325   1.090, 2.399 2.24 0.567   1.362, 3.680 
To make childbearing 
decisions 
Somewhat imp 1.04 0.698 0.028 0.284, 3.869 0.66 0.169 0.189 0.397, 1.087 1.06 0.344 0.7734 0.561, 2.002 
Very imp 0.351 0.145   0.156, 0.789 1.02 0.299   0.580, 1.818 0.8 0.267   0.418, 1.542 
To know if I need to get 
cancer screening  
Somewhat imp 1.014 0.272 0.959 0.598, 1.718 1.21 0.554 0.0002 0.495, 2.973 0.83 0.367 <0.0005 0.353, 1.976 
Very imp  *      2.1 0.929   0.888, 5.002 2.27 0.993   0.965, 5.354 
To reduce uncertainty 
  
Somewhat imp 0.215 0.158 0.111 0.051, 0.908 1.16 0.275 0.0211 0.726, 1.847 1.02 0.258 <0.0005 0.624, 1.678 
Very imp 0.229 0.166   0.056, 0.951 1.59 0.38   0.997, 2.542 2.21 0.588    1.309, 3.720 
RISKS / LIMITATIONS   OR SE P >Chisq 95% CI OR SE P >Chisq 95% CI OR SE P >Chisq 95% CI 
Worried about losing my 
insurance  
Somewhat imp 0.518 0.169 <0.0005 0.273, 0.985 0.88 0.144 0.743 0.640, 1.215 0.64 0.117 0.0009 0.450, 0.918 
Very imp 0.233 0.075   0.124, 0.440 0.97 0.176   0.675, 1.381 0.46 0.104   0.295, 0.715 
Worried about loss of 
confidentiality  
Somewhat imp 0.32 0.1 <0.0005 0.174, 0.591 0.77 0.134 0.311 0.543, 1.082 0.55 0.113 0.0026 0.369, 0.827 
Very imp 0.243 0.087   0.120, 0.493 0.9 0.2   0.583, 1.392 0.55 0.137   0.338, 0.899 
Worried about 
stigmatization  
Somewhat imp 0.275 0.094 <0.0005 0.142, 0.536 0.83 0.199 0.679 0.516, 1.329 0.72 0.222 0.476 0.395, 1.321 
Very imp 0.181 0.093   0.066, 0.494 1.13 0.405   0.556, 2.281 0.76 0.315   0.338, 1.715 
Do not trust modern 
medicine  
Somewhat imp 0.374 0.159   0.162, 0.863 0.71 0.147 0.22 0.476, 1.069 0.54 0.179 0.034 0.284, 1.036 
Very imp 0.097 0.058 0.0001 0.030, 0.312 0.78 0.257   0.409, 1.491 0.39 0.184   0.154, 0.984 
Nothing that can be done to 
prevent getting cancer  
Somewhat imp 0.64 0.189 0.011 0.272, 1.072 0.59 0.103 0.011 0.422, 0.835 0.44 0.091 0.0002 0.297, 0.664 
Very imp 0.396 0.131   0.207, 0.759 0.85 0.154   0.596, 1.212 0.97 0.216   0.630, 1.506 
Concerned about the effect it 
would have on my family  
Somewhat imp 0.373 0.132 <0.0005 0.187, 0.746 0.84 0.135 0.384 0.614, 1.151 0.66 0.123 0.059 0.457, 0.950 
Very imp 0.218 0.073   0.114, 0.419 0.82 0.127   0.602, 1.108 0.72 0.142   0.496, 1.067 
Concerned that I could not 
handle it emotionally  
Somewhat imp 0.556 0.184 <0.0005 0.291, 1.064 0.73 0.112 0.054 0.539, 0.985 0.79 0.141 0.0013 0.554, 1.120 
Very imp 0.129 0.045   0.066, 0.254 0.69 0.129   0.480, 0.995 0.43 0.101   0.273, 0.684 
 
OR- odds ratio, SE- standard error, CI- confidence interval. 
*omitted due to collinearity 
‘Not at all important’ - Reference category for the first 14 items.  
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Table-4: Factors affecting overall attitude (risks, limitations and cultural factors) towards testing 
Theta_GRM Coeff SE P>|t| 95% CI 
Gender  -0.252 0.077 0.001 -0.404, -0.100 
Family History -0.038 0.115 0.738 -0.264, 0.188 
Income (£)         
10K-20K (£) -0.006 0.239 0.98 -0.476, 0.464 
20K-30K (£) -0.016 0.253 0.95 -0.515, 0.483 
30K-40K (£) -0.027 0.24 0.911 -0.500, 0.447 
40K-50K (£) 0.036 0.23 0.876 -0.417, 0.489 
>50K (£) -0.164 0.22 0.456 -0.597, 0.269 
Children  0.335 0.117 0.005 0.103, 0.506 
Education -0.3 0.087 0.001 -0.472, -0.129 
Marital Status 0.057 0.107 0.593 -0.153, 0.268 
Age -0.002 0.003 0.496 -0.007, 0.003  
HADS Total 0.017 0.007 0.018 0.003, 0.03 
Knowledge 0.002 0.018 0.914 -0.034, 0.038 
Cancer Risk 
Perception 0.0002 0.0006 0.783 -0.001, 0.001 
 
Coeff- coefficient, SE- standard error, CI- confidence interval, K- thousand, HADS- hospital anxiety and depression scale 
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Table S1- Cultural/Religious factors affecting Attitudes towards BRCA-testing  
 
CULTURAL / RELIGIOUS    OR SE P >Chisq 95% CI OR SE 
P 
>Chisq 95% CI OR SE P >Chisq 95% CI 
Worried that the study 
is too focused on 
Jewish community  
Somewhat 0.417 0.134 0.0067 0.222, 0.784 0.5 0.092 0.0005 
0.347, 
0.716 0.33 0.074 <0.0005 0.22, 0.51 
Yes, 
definitely 0.293 0.293   
0.076, 
1.127 1.37 0.615   
0.571, 
3.306 0.57 0.435 0.13 0.13, 2.5 
Concerned that being a 
gene carrier might alter 
marriage prospects for 
myself or my family 
members  
Somewhat 0.357 0.12 0.0024 0.185, 0.690 0.6 0.135 0.07 
0.382, 
0.932 0.44 0.101 0.0017 0.28, 0.69 
Yes, 
definitely 0.38 0.212   
0.127, 
1.138 0.77 0.285   
0.373, 
1.592 1.1 0.614   0.37, 3.28 
Concerned genetic 
information might be 
used to single out 
individuals of a 
particular ethnic group  
Somewhat 0.462 0.135 0.0059 0.260, 0.822 0.55 0.116 0.018 
0.363, 
0.832 0.45 0.093 0.0004 0.30, 0.68 
Yes, 
definitely 0.307 0.164   
0.108, 
0.876 0.87 0.352   
0.392, 
1.922 0.52 0.233   0.22, 1.25 
Potential to improve 
the health of the Jewish 
Community will 
influence my decision 
to be tested  
Somewhat 0.936 0.284 0.564 0.517, 1.696 0.65 0.116 0.055 
0.460, 
0.924 0.46 0.103 0.0007 0.30, 0.71 
Yes, 
definitely 1.27 0.38   
0.707, 
2.284 0.79 0.126   
0.582, 
1.085 0.72 0.144   0.49, 1.07 
 
OR- odds ratio, SE- standard error, CI- confidence interval. 
 ‘Definitely not’ - Reference category for the last 4 items.  
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